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Abstract
Background: It was reported recently that resveratrol could sensitize a number of cancer cells to the antitumoral
effects of some conventional chemotherapy drugs. The current study was designed to investigate whether
resveratrol could sensitize leukemic cells to proteasome inhibitors.
Methods: Leukemic cells were treated with MG132 alone or in combination with resveratrol. Cell viability was
investigated using MTT assay, and induction of apoptosis and cell cycle distribution was measured using flow
cytometry. Western blot and real-time RT-PCR were used to investigate the expression of FOXO1 and p27
Kip1. CHIP
was performed to investigate the binding of FOXO1 to the p27
Kip1 promoter.
Results: Resveratrol strongly reduced cytotoxic activities of proteasome inhibitors against leukemic cells. MG132 in
combination with resveratrol caused cell cycle blockade at G1/S transition via p27
Kip1 accumulation. Knockdown of
p27
Kip1 using siRNA dramatically attenuated the protective effects of resveratrol on cytotoxic actions of proteasome
inhibitors against leukemic cells. Resveratrol induced FOXO1 expression at the transcriptional level, while MG132
increased nuclear distribution of FOXO1. MG132 in combination with resveratrol caused synergistic induction of
p27
Kip1 through increased recruitment of FOXO1 on the p27
Kip1 promoter.
Conclusions: Resveratrol may have the potential to negate the cytotoxic effects of proteasome inhibitors via
regulation of FOXO1 transcriptional activity and accumulation of p27
Kip1.
Background
The ubiquitin proteasome system (UPS) is the major
proteolytic system encountered in the cytoplasm and
nucleus of virtually all nucleated eukaryotic cells [1].
Tight regulation of UPS-mediated proteolysis is main-
tained to control half-lives of proteins involved in cell
cycle regulation, transcriptional control, antigen proces-
sing, angiogenesis, and removal of incorrectly folded or
damaged proteins [2]. It has become evident that pro-
teasomal function is essential for cell survival and that
inhibition of proteasomal activity is a powerful means to
induce cytotoxicity in many cancer cells derived from
various histology [3,4].
Resveratrol, a naturally occurring polyphenolic com-
pound, is enriched in a variety of food sources, such as
grapes, peanuts and red wine. A number of previous stu-
dies have reported that resveratrol can inhibit the growth
of human cancer cells when it is present alone at rather
high concentrations (usually >50 uM) [5-8]. In addition,
it has been reported when it is used in combination with
other anticancer drugs, resveratrol can avoid some of the
debilitating side effects and sensitize a number of cancer
cell lines to the anticancer actions of some other conven-
tional chemotherapy drugs such as TNFa, paclitaxel,
et al., as well as radiotherapy [5-7,9-13]. Accumulating
data support that proteasome inhibitors have the poten-
tial to reduce the viability of proliferating cells, while
nonproliferating, quiescent cells, in short-term experi-
ments at least, are remarkably protected against apopto-
sis induced by proteasome inhibitors [14,15]. One
common feature of quiescent cells is the upregulation of
p27
Kip1, a ubiquitous cyclin dependent kinase inhibitor
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general property of cells that switch to a nonproliferative
phenotype [16,17]. In addition, it has been reported that
p27
Kip1-mediated cell cycle arrest at G1/S transition is
required for protection against proteasome inhibitors
[18].
In the current study, we have found that resveratrol
dramatically protects leukemic cells from cytotoxic
actions of proteasome inhibitors via p27
Kip1-mediated
G1/S cell cycle arrest. In addition, we have demon-
strated that synergistic induction of p27
Kip1 via FOXO1
by MG132 in combination with resveratrol is, at least
partly, responsible for the protective effects of resvera-
trol. In light of the recent interest in the resveratrol for
its possible use in combination chemotherapy regimens
and widespread use of resveratrol among cancer
patients, this study calls for more caution for leukemia
patients using resveratrol as a dietary adjuvant during
treatment with proteasome inhibitors.
Methods
Culture of multiple leukemic cell lines
K562, U937, NB4, Daudi and Raji cell lines were main-
tained in RPMI1640 medium (Sigma-Aldrich, Saint
Louis, MO) supplemented with 10% fetal bovine serum
(FBS, Sigma-Aldrich, Saint Louis, MO).
Chemicals
MG132, epoxomycin, PSI and lactacystin were pur-
chased from Calbiochem. 0.02% DMSO was used as
vehicle control.
Cell viability assays
For cell viability assays, cells were plated in 96-well
dishes (1 × 10
4 cells per well) and treated with different
effectors for 24 h. Cell viability was assessed using the
3-(4,5-dimethylthiazol-2-thiazolyl)-2,5-diphenyl tetrazo-
lium bromide (MTT) assay (Chemicon, Bedford, MA)
according to the manufacturer’s instruction.
Detection of apoptotic cells
For cell death assays, cells were washed twice in phos-
phate-buffered saline and then stained with Annexin V-
FITC (Biovision, Mountainview, CA) and propidium
iodide (PI, Sigma-Aldrich) according to the manufac-
turer’s instructions. After staining with annexin V-FITC
and PI, samples were analyzed by fluorescence-activated
cell scanner (FACScan) flow cytometer (Becton Dickin-
son, Franklin Lakes, NJ).
Analysis of the cell cycle by flow cytometry
Cells were exposed to different concentrations of resver-
atrol for 24 h. The cells were fixed in 70% ethanol and
stained with 50 μg/ml of propidium iodide (PI). The
fluorescence was measured using the Becton Dickinson
FACScan (Bedford, MA). Distribution of cells in distinct
cell cycle phase was determined using ModFIT cell
cycle analysis software.
Western blot analysis
Cells were lysed in lysis buffer (20 mM Tris-HCl, 150 mM
NaCl, 2 mM EDTA, 1% Triton-X100 and protease inhibi-
tor cocktail (Sigma-Aldrich, Saint Louis, MO). Cell extract
protein amounts were quantified using the BCA protein
assay kit. Equivalent amounts of protein (25 μg) were
separated using 12% SDS-PAGE and transferred to PVDF
membrane (Millipore Corporation, Billerica, MA).
Preparation of cytoplasmic and nuclear extract
After treatment, cells were lysed in buffer A (containing
10 mM HEPES, pH 7.9, 1.5 mM MgCl2,1 0m MK C l ,
0.5 mM DTT, 1% Nonidet P-40 and protease inhibitor
cocktail) and centrifuged at 12,000 g for 10 min at 4°C.
The supernatant was collected and used as the cytoplas-
mic extracts. The nuclei pellet was resuspended in buf-
fer B (20 mM HEPES, pH7.9, containing 1.5 mM
MgCl2,4 5 0m MN a C l ,2 5 %g l y c e r o l ,0 . 2m ME D T A ,
0.5 mM DTT and protease inhibitor cocktail) and agi-
tated fro 60 min at 4°C, and the nuclear debris was
spun down at 20,000 g for 15 min. The supernatant
(nuclear extract) was collected. Antibodies against His-
tone H2B and LDH were used as loading controls for
nuclear and cytosolic proteins, respectively.
Chromosomal immunoprecipitation (ChIP) assay
ChIP assays were performed using a kit from Upstate Bio-
techonology Inc. (Lake Placid, NY) according to the sup-
plied protocol. In brief, cells were exposed to different
treatment and fixed with 1% formaldehyde in PBS to
cross-link chromatin. Cell lysates were prepared and soni-
cated on ice to break chromatin DNA to an average length
of 400 bp. After a preclearing step, immunoprecipitation
was carried out at 4°C overnight with anti-FOXO1 anti-
body or normal goat IgG (negative control antibody).
Immune complexes were collected with salmon sperm
DNA saturated protein A-agarose beads. After extensive
washing the immunoprecipitated complexes were eluted
with 0.1 M NaHCO3 and 1% SDS, and then protein-DNA
cross-links were reversed by incubating at 65°C for
5 hours. DNA was purified using proteinase K digestion,
phenol: chloroform extraction and ethanol precipitation.
Real-time PCR was performed using primers specific
for the p27
Kip1 sequence between -237 and +15 (forward:
5’-AGGTTTGTTGGCAGCAGTACC-3’ and reverse:
5’-AGGCTGACGAAGAAGAAAATG-3’) to generate a
252 bp amplification product containing the FOXO
response element [19,20]. A standard curve was prepared
using serial dilutions of PCR products using genomic
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Kip1 promoter frag-
ment that was present in the immunoprecipitation and
input fractions was calculated from the standard curve.
The input represents 1% of the material used in the immu-
noprecipitation assay. The results were expressed as the
immunoprecipitation/input ratios of the PCR products
were used for comparison.
Small interfering RNA
The siRNA sequences used here were as follows: siRNA
against p27
Kip1 (sip27
Kip1), GGAGCAAUGCGCAG-
GAAUAUU; siRNA against FOXO1 (siFOXO1), CCCU-
GUAACUGACAGACCAAAU. The scramble nonsense
siRNA (scramble; CCGUAUCGUAAGCAGUACU) that
has no homology to any known genes was used as con-
trol. The cells were transfected using FuGENE 6 accord-
ing to the manufacturer’s instruction.
Statistics
The statistical significance of the difference was analyzed
by ANOVA and post hoc Dunnett’s test. Statistical sig-
nificance was defined as p < 0.05. All experiments were
repeated three times, and the results are presented as
mean ± standard deviation (SD) of the three repeated
experiments performed in triplicate.
Results
Resveratrol suppresses the cytotoxic effects of
proteasome inhibitors in K562 leukemic cells
Cell viability of K562 cells was decreased upon treatment
with resveratrol when used higher concentration than
50 μM, while 1-20 μM of resveratrol had no obvious effects
on K562 cell viability within 24 h (Figure 1A). Viability of
K562 cells treated with MG132 demonstrated a dose-
dependent decrease within 24 h (Figure 1B). MTT assay of
K562 cells demonstrated that resveratrol significantly
prevented the cytotoxicity induced by MG132 in a dose-
dependent manner (Figure 1C). As low as 2 μMo fr e s v e r a -
trol demonstrated obvious protective effect, with the
maximal protective effect observed at the concentrations
among 5 to 20 μM (Figure 1C). Interestingly, even under
conditions where resveratrol was obviously toxic at
the concentrations of 50 to 100 μM, it was still able to
antagonize the cytotoxic effect of MG132 (Figure 1C).
MG132-induced apoptosis was further determined by
flow-cytometric analysis of K562 cells labeled with propi-
dium iodide (PI) and annexin V. Consistent with our pre-
vious report [21], resveratrol alone caused only about 12%
of apoptotic cells within 24 h when applied even at concen-
trations of 100 μM (Figure 1D). The increase in apoptotic
cells induced by 5 μM MG132 alone was markedly abro-
gated by the addition of resveratrol (Figure 1D). Further-
more, the addition of resveratrol significantly inhibited
MG132-induced PARP cleavage to the characteristic
apoptotic 89 kDa fragment (Figure 1E). These results
confirmed the protective effect of resveratrol on MG132-
induced apoptosis in K562 cells.
Resveratrol acts as a survival factor in human leukemic
cells against proteasome inhibition
We then further determined whether the protective effect
of resveratrol was a general phenomenon against protea-
some inhibitors. Since 5-20 μMo fr e s v e r a t r o ld e m o n -
strated the maximal protective effect on MG132-mediated
cytotoxicity of K562 cells (Figure 1C-E), we used 5 μMo f
resveratrol in the following experiments. Three structu-
rally different proteasome inhibitors, namely PSI (5 nM),
lactacystin (10 μM) as well as epoxomicin (50 nM) were
able to induce up to 40-60% apoptosis of K562 cells within
24 h of incubation (Figure 2A). A marked protection of
K562 against the cytotoxic effects of all three proteasome
inhibitors could be observed when used in combination
with resveratrol (Figure 2A). To further test the potential
effect of resveratrol as a survival factor, we extended our
studies to various human leukemic cell lines. Resveratrol
also exerted a protective effect against cytotoxicity induced
by MG132 in other four human leukemic cell lines, NB4,
U937, Daudi and Raji (Figure 2B). These findings indicated
that resveratrol antagonized the cytotoxic actions of pro-
teasome inhibitors in a variety of human leukemic cell
lines.
Involvement of p27
Kip1-mediated G1/S arrest in the
protective effects of resveratrol against cytotoxicity
induced by MG132
5 μM Resveratrol primarily increased cells in the S
phase, whereas 5 μM MG132 predominantly caused an
increase of cells in the S and G2/M phase (Figure 3A),
as determined by propidium iodide (PI) staining and
FACS analysis of cells incubated with resveratrol or
MG132 for 24 h. MG132 in combination with resvera-
trol significantly decreased the population of cells in the
S phase, but increased the population in the G1 phase
when compared with MG132 alone (Figure 3A). Since
rapidly proliferating cells were much sensitive to protea-
some inhibitor-mediated apoptosis versus their quies-
cent counterparts [15,22-26], furthermore, blockade at
G1/S transition appears to be a general property of cells
that switch to a nonproliferative phenotype [16,17],
these results suggested that antagonism of resveratrol
against MG132 might be the result of blocking cell cycle
progression at the G1/S transition and thus preventing
the cell from proliferation.
The cyclin dependent kinase (CDK) inhibitor p27
Kip1
is an important regulator of cell cycle progression con-
trolling the transition from G1 to S-phase [27], in addi-
tion, it has also been reported that p27
Kip1-mediated cell
cycle arrest at the G1/S transition is required to confer
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Figure 1 Resveratrol blocks the cytotoxic effects of MG132 in K562 cells. A-B, Cell viability of K562 cells was determined using MTT assay
after treatment with various concentrations of resveratrol (A) and MG132 (B) for 24 h, respectively. C, The percentage of viable cells was
determined using MTT assay after treatment with 5 μM MG132 and various concentrations of resveratrol for 24 h. D, Cells were treated with 5
μM MG132 and various concentration of resveratrol for 24 h, apoptotic cells were analyzed. A-D, The results are presented as mean of three
independent experiments performed in triplicate, and error bars represent standard deviation. E, K562 cells were treated with 5 μM MG132 and
various concentration of resveratrol for 24 h, and Western blot analysis was performed. Representative blot from three independent experiments
with similar results was shown. *, P < 0.05; **, P < 0.01.
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Page 4 of 10protection for K562 cells against proteasome inhibitors
[18]. Therefore, we investigated whether p27
Kip1 also
contributed to the protective effect of resveratrol against
proteasome inhibitors-induced cytotoxicity in leukemic
cells. Resveratrol or MG132 alone increased p27
Kip1,
combinational treatment with MG132 and resveratrol
further enhanced the expression of p27
Kip1 (Figure 3B).
To clarify the potential involvement of p27
Kip1 accumu-
lation in protective effects of resveratrol, p27
Kip1 expres-
sion was knocked down using the p27
Kip1 specific
siRNA. Accumulation of p27
Kip1 mediated by MG132,
resveratrol, or their combination was decreased in
p27
Kip1-knockdown cells (Figure 3C). Knockdown of
p27
Kip1 provided marginal protection against MG132
alone-mediated apoptosis (Figure 3D). Importantly, the
protective effect of resveratrol against MG132 was sig-
nificantly weakened by p27
Kip1 Knockdown (Figure 3D).
These results indicated that resveratrol-induced p27
Kip1,
at least partially contributed to the resveratrol-mediated
attenuation of the apoptotic effects of MG132.
Involvement of FOXO1 in upregulation of p27
Kip1 induced
by resveratrol and MG132
We then examined the mechanism underlying upregula-
tion of p27
Kip1 by resveratrol or MG132. Real-time PCR
showed that resveratrol alone increased p27
Kip1 mRNA,
whereas MG132 alone had no obvious effect on p27
Kip1
mRNA expression (Figure 4A). Co-administration of
resveratrol with MG132 significantly augmented p27
Kip1
mRNA when compared with resveratrol alone (Figure 4A).
To determine whether de novo RNA synthesis is required
for the elevation of p27
Kip1, actinomycin D, an inhibitor of
RNA synthesis was pre-administrated before treatment
with resveratrol alone or in combination with MG132.
Actinomycin D completely blocked upregulation of p27
Kip1
mRNA by resveratrol alone or in combination with
MG132 (Figure 4B).
Resveratrol enhances the recruitment of transcription
factor forkhead box class O transcription factor (FOXO)1
to the FOXO-binding element [28,29]. In addition,
FOXO1 has been shown to trans-activate p27
Kip1 expres-
sion [30-32]. To verify whether there is a correlation
between resveratrol-mediated induction of p27
Kip1 and
the activation of FOXO1 pathway, we tested the expres-
sion of FOXO1 by real-time RT-PCR and Western blot.
FOXO1 expression was notably increased with resvera-
trol treatment (either in resveratrol alone or in combina-
tion with MG132 group) compared with the groups
treated with vehicle or MG132 alone, whereas there was
no obvious difference between resveratrol alone and in
combination with MG132 (Figure 4C). Investigation of
the cellular distribution of FOXO1 demonstrated that
FOXO1 localized primarily to the cytoplasm in the
vehicle-treated cells, nuclear FOXO1 was significantly
increased in cells treated with resveratrol alone or in
combination with MG132 (Figure 4D). With some lesser
extent, MG132 alone also increased nuclear localization
of FOXO1 (Figure 4D). To see whether the different dis-
tribution of FOXO1 is ascribed to the synergistic upregu-
lation of p27
Kip1 by MG132 in combination with
resveratrol via recruitment of FOXO1 to the FOXO-
binding site of p27
Kip1 promoter, we then performed
ChIP analysis and found that binding of FOXO1 to the
p27
Kip1 promoter was enhanced in cells co-treated with
resveratrol and MG132, compared with those treated
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Figure 2 Protective roles of resveratrol against proteasome
inhibition in a panel of leukemic cells. A, K562 cells were treated
with 5 nM PSI, 10 μM lactacystin or 50 nM epoxomicin alone or
combination with 5 μM resveratrol for 24 h. Apoptotic cells were
analyzed using Annexin-FITC/PI double staining followed by FACS
analysis. B, A panel of leukemic cells was treated with 5 μM MG132
alone or combination with 5 μM resveratrol for 24 h, and apoptotic
cells were analyzed using Annexin-FITC/PI double staining followed
by FACS analysis. The results are presented as mean of three
independent experiments performed in triplicate, and error bars
represent standard deviation. *, P < 0.05; **, P < 0.01.
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A, The panel of leukemic cells was treated with 5 μM resveratrol or 5 μM MG132 alone or combination for 24 h and cell cycle distribution was
measured using FACS analysis. Representative graph from three independent experiments with similar results was shown. B, K562 cells were
treated as A, and Western blot analysis was performed. Representative blot from three independent experiments with similar results was shown.
C, K562 cells were transfected with scramble or p27
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for another 24 h. p27
Kip1 expression levels were investigated using Western blot analysis. Representative blot from three independent
experiments with similar results was shown. D, Cells were treated as C, and apoptotic cells were measured using Annexin-FITC/PI double staining
followed by FACS analysis. The results are presented as mean of three independent experiments performed in triplicate, and error bars represent
standard deviation. *, P < 0.05; **, P < 0.01.
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Figure 4 Involvement of FOXO1 in induction of p27
Kip1 mediated by resveratrol and MG132.A ,K 5 6 2c e l l sw e r et r e a t e dw i t h5μM
resveratrol or 5 μM MG132 alone or combination for 8 h and real-time RT-PCR was performed. The results are presented as mean of three
independent experiments performed in triplicate, and error bars represent standard deviation. B, K562 cells were pretreated with vehicle or
actinomycin D for 1 h, then treated with resveratrol alone or combination with MG132 for additional 8 h, then real-time RT-PCR was performed.
The results are presented as mean of three independent experiments performed in triplicate, and error bars represent standard deviation. C,
K562 cells were treated with 5 μM resveratrol or 5 μM MG132 alone or combination, FOXO1 mRNA and protein levels were investigated using
real-time RT-PCR and Western blot, respectively. The results of real-time RT-PCR are presented as mean of three independent experiments
performed in triplicate, and error bars represent standard deviation. Representative blot from three independent experiments with similar results
was shown. D, K562 cells were treated as C, Western blot was performed on cytosolic and nuclear proteins, respectively. Representative blot
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for 8 h. Cross-linked chromatin was extracted and immunoprecipitated with an anti-FOXO1 antibody. Immunoprecipitated DNA was amplified by
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deviation. F, K562 cells were transfected with scramble or siRNA against FOXO1 (siFOXO1) for 48 h, then treated with MG132 or resveratrol alone
or combination for additional 24 h, and Western blot was performed. Representative blot from three independent experiments with similar
results was shown. *, P < 0.01 vs control; #, P < 0.01.
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Page 7 of 10with resveratrol alone (Figure 4E). To confirm whether
FOXO1 is responsible for upregulation of p27
Kip1,w e
used specific siRNA against FOXO1 to verify its effect on
the expression of p27
Kip1. Specific siRNA against FOXO1
effectively suppressed upregulation of FOXO1 induced
by resveratrol treatment (Figure 4F). Importantly, conco-
mitant with FOXO1 reduction, resveratrol-induced
p27
Kip1 expression was suppressed in cells transfected
with siRNA against FOXO1 (Figure 4F).
Discussion
Single agent of proteasome inhibitor resulted in signifi-
cant responses in leukemic cells and the combination of
proteasome inhibitors and other chemotherapeutic
drugs enhanced its antitumoral efficacy [3,33-37]. Initi-
ally, the experiments were planned to test whether
resveratrol could sensitized K562 cells to the anticancer
actions of proteasome inhibitors. To our surprise,
resveratrol did not promote, but rather attenuated the
apoptotic effects of MG132 in cultured K562 cells. We
further extended our investigation using a panel of leu-
kemic cells and found that resveratrol also attenuated
the cytotoxic actions of MG132 in NB4, U937, Raji and
Daudi cells. Furthermore, resveratrol also compromised
the apoptotic effects of other three structurally different
proteasome inhibitors, PSI, epoxomicin and lactacystin.
This was consistent with the previous study that resver-
atrol exerted its protective effects against proteasome
inhibitor-induced cellular damages in human skeletal
myotubes [38]. Consistent with our previous report [21],
in the current study, we found that resveratrol per se
did not cause obvious apoptosis when less than 100 μM
concentration was used within 24 h. Chakraborty PK
et al. reported that treatment with 40 μM resveratrol for
48 h induced apoptosis of K562 cells [39]. The different
effects of resveratrol on apoptosis of K562 cells might
be ascribed to different period of exposure. Alterna-
tively, Chakraborty PK et al. used subG1 fractions repre-
sented as apoptotic cells [39], while in the current study,
we used Annexin V/PI double staining followed by flow
cytometry to detect apoptotic cells. The different meth-
ods used in these studies might contribute to the differ-
ent apoptotic actions of resveratrol. The higher
cytoprotective effect of resveratrol on cytotoxic actions
of proteasome inhibitors was observed when it was used
at 5-20 μM concentration. We observed that 50-100 μM
resveratrol was slightly cytotoxic for K562 cells, which
could explain why this concentration exerted a lower
cytoprotective action compared with 20 μM resveratrol.
Even this, when cells were concurrently incubated with
100 μM of resveratrol, the apoptosis observed after
exposure to MG132 was significantly lower than the one
observed in the cells exposed to MG132 alone, indicat-
ing that even when 100 μM resveratrol could induce a
certain degree of cytotoxicity in these cells, at the same
time exerted a cytoprotective action against cytotoxicity-
mediated by proteasome inhibition. Resveratrol was
reported to be abundant in grapes, blueberries and pea-
nuts. In grapes, its highest concentration was in the skin
(50-100 μg per gram), thereby making red wines (but
n o tw h i t ew i n e s )t h er i c h e s td i e t a r ys o u r c e[ 4 0 ] .I n
plasma, it bound with lipoproteins and albumin which
facilitated its carrier-mediated cellular uptake [41]. In
experimental animals, resveratrol was rapidly metabo-
lized by the liver and its plasma half-life remained quite
low [42], however, in human, about 70% of orally admi-
nistered resveratrol (25 mg) was absorbed with a peak
plasma level of ~2 μM and a half-life of ~10 h [43]. In
the current study, we found that 5 μMo fr e s v e r a t r o l
could antagonize the cytotoxic effects of proteasome
inhibitors. Therefore, concurrent intake of resveratrol
products should be discreet.
Arrest at G1/S transition appeared to be a general
property of cells that switched to a nonproliferative phe-
notype [16,17,44]. Compared with nonproliferating,
quiescent cells, proliferating cells were much more sensi-
tive to cytotoxicity induced by proteasome inhibitors
[14,15]. In the current study, we found that combination
of resveratrol and MG132 significantly increased propor-
tion of cells in G1 fraction, therefore, protective effects of
resveratrol against proteasome inhibition might be the
result of blocking cell cycle progression at the G1/S tran-
sition and thus preventing the cells from proliferation.
Proteasome inhibitor-induced apoptosis generally was
accompanied by the accumulation of p27
Kip1, a universal
CDK-cyclin inhibitor responsible for cell cycle arrest at
G1/S transition [45]. A rather broad spectrum of effects
were ascribed to elevated levels of p27
Kip1 protein ran-
ging from proapoptotic functions in various systems to
survival-promoting properties in others. Conflicting
observations were also reported regarding the role of
p27
Kip1 in apoptosis induced by proteasome inhibitors.
As overexpression of p27
Kip1 in various tumor cell lines
was sufficient to induce apoptosis in various cancer cell
lines [46,47], it had therefore been deduced that cytotoxi-
c i t yi n d u c e db yp r o t e a s o m ei n h i b i t o r sc o u l db ed u et o
the uncoordinated upregulation of p27
Kip1 [45,48,49].
These pro-apoptotic properties were also consistent with
the notion that p27
Kip1 exerted the task of a tumor sup-
pressor gene. In contrast to these observations, the cyto-
toxic effects of proteasome inhibitors in general appeared
to be selective for proliferating cells, but quiescent cells
generally with high levels of p27
Kip1 in nucleus seemed to
be protected [14,15]. For example, primary endothelial
cells which became contact inhibited upon reaching con-
fluence displayed a remarkable degree of resistance
against apoptosis induced byp r o t e a s o m ei n h i b i t o r si n
the presence of increased steady state levels of p27
Kip1,
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[15]. Similar observations were also observed in different
cancer cell lines engineered to overexpress p27
Kip1
[50-52]. Likewise, inducible overexpression of p27
Kip1
protected K562 cells against induction of apoptosis by
proteasome inhibitors [18]. Since proliferation and differ-
entiation were usually mutually exclusive, it was not sur-
prised that cell cycle arrest at G1/S transition and p27
Kip1
was also involved in the differentiation of erythroid pre-
cursors [53,54]. Thus, induction of cell differentiation via
accumulation of p27
Kip1 and G1/S arrest might also con-
tribute to the protective roles of resveratrol against pro-
teasome inhibition-mediated cytotoxicity.
A major consequence of the anti-apoptotic properties
of p27
Kip1 appeared that high levels of p27
Kip1 in tumor
cells might not be always good news for cancer patients:
high levels of active p27
Kip1 within tumor cells might
indicate that although less aggressive and more slowly
growing, this tumor might be more difficult to be
attacked by treatment with proteasome inhibitors or
other chemotherapeutic drugs.
In conclusion, the present study demonstrated that
resveratrol had the potential to negate the therapeutic
efficacy of proteasome inhibitors in leukemic cells and
suggested that intake of resveratrol-related products
might be contraindicated for patients undergoing treat-
ment with proteasome inhibitors. Considering the wide-
spread use of resveratrol among cancer patients, further
investigations should be necessary to elucidate the
in vivo significance of these findings, which in turn
might inform the need for dietary advice on the con-
sumption of resveratrol during chemotherapy with pro-
teasome inhibitors.
Conclusions
Resveratrol may have the potential to negate the cyto-
toxic effects of proteasome inhibitors via regulation of
FOXO1 transcriptional activity and accumulation of
p27
Kip1. Further investigations should be performed to
elucidate the in vivo significance of these findings,
which in turn might inform patients undergoing the
chemotherapy with proteasome inhibitors to avoid
intake of resveratrol-related products.
Acknowledgements
This work was partly supported by National Natural Science Foundation of
China (30870522, 31070697), Foundation of Liaoning Educational Committee
(L2010561, L2010616 and 2009225012).
Author details
1Department of Biochemistry & Molecular Biology, China Medical University,
Shenyang 110001, PR China.
2Key Laboratory of Cell Biology, Ministry of
Public Health, and Key Laboratory of Medical Cell Biology, Ministry of
Education, China Medical University, Shenyang 110001, PR China.
3Department of Endocrinology and Metabolism, the 1stAffiliated Hospital,
China Medical University, Shenyang 110001, PR China.
Authors’ contributions
XFN carried out the cell culture and molecular studies, and participated in
the data analysis. BQL carried out ChIP, nuclear fractionation and flow
cytometry. ZXD participated in real-time PCR and cell culture. YYG
participated in flow cytometry and MTT assay. CL participated in cell culture
and flow cytometry.NL participated in the DNA cloning and Western blot
analysis. YG participated in manuscript proofreading. HQW conceived of the
study, and participated in manuscript drafting and coordinate. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 October 2010 Accepted: 19 March 2011
Published: 19 March 2011
References
1. Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 1998,
67:425-479.
2. Baumeister W, Walz J, Zuhl F, Seemuller E: The proteasome: paradigm of a
self-compartmentalizing protease. Cell 1998, 92(3):367-380.
3. Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, Santos T, Grassian A,
Ghaffari S, Wu C, Yeckes-Rodin H, et al: Proteasome inhibition causes
regression of leukemia and abrogates BCR-ABL-induced evasion of
apoptosis in part through regulation of forkhead tumor suppressors.
Cancer Res 2009, 69(16):6546-6555.
4. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De
Raeve H, Coulton L, Van Camp B, Croucher P, et al: Bortezomib alone or in
combination with the histone deacetylase inhibitor JNJ-26481585: effect
on myeloma bone disease in the 5T2 MM murine model of myeloma.
Cancer Res 2009, 69(13):5307-5311.
5. Fulda S, Debatin KM: Sensitization for tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis by the chemopreventive
agent resveratrol. Cancer Res 2004, 64(1):337-346.
6. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW: Resveratrol
sensitizes androgen independent prostate cancer cells to death-receptor
mediated apoptosis through multiple mechanisms. Prostate 2007,
67(15):1641-1653.
7. Fulda S, Debatin KM: Sensitization for anticancer drug-induced apoptosis
by the chemopreventive agent resveratrol. Oncogene 2004,
23(40):6702-6711.
8. Zhou R, Fukui M, Choi HJ, Zhu BT: Induction of a reversible, non-cytotoxic
S-phase delay by resveratrol: implications for a mechanism of lifespan
prolongation and cancer protection. Br J Pharmacol 2009, 158(2):462-474.
9. Kubota T, Uemura Y, Kobayashi M, Taguchi H: Combined effects of resveratrol
and paclitaxel on lung cancer cells. Anticancer Res 2003, 23(5A):4039-4046.
10. Jazirehi AR, Bonavida B: Resveratrol modifies the expression of apoptotic
regulatory proteins and sensitizes non-Hodgkin’s lymphoma and
multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer
Ther 2004, 3(1):71-84.
11. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK:
Resveratrol sensitizes melanomas to TRAIL through modulation of
antiapoptotic gene expression. Exp Cell Res 2008, 314(5):1163-1176.
12. Scarlatti F, Sala G, Ricci C, Maioli C, Milani F, Minella M, Botturi M, Ghidoni R:
Resveratrol sensitization of DU145 prostate cancer cells to ionizing
radiation is associated to ceramide increase. Cancer Lett 2007,
253(1):124-130.
13. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U,
Nair AS, Shishodia S, Aggarwal BB: Resveratrol inhibits proliferation,
induces apoptosis, and overcomes chemoresistance through down-
regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic
and cell survival gene products in human multiple myeloma cells. Blood
2007, 109(6):2293-2302.
14. Drexler HC: Activation of the cell death program by inhibition of
proteasome function. Proc Natl Acad Sci USA 1997, 94(3):855-860.
15. Drexler HC, Risau W, Konerding MA: Inhibition of proteasome function
induces programmed cell death in proliferating endothelial cells. Faseb J
2000, 14(1):65-77.
16. Hirano M, Hirano K, Nishimura J, Kanaide H: Transcriptional up-regulation
of p27(Kip1) during contact-induced growth arrest in vascular
endothelial cells. Exp Cell Res 2001, 271(2):356-367.
Niu et al. BMC Cancer 2011, 11:99
http://www.biomedcentral.com/1471-2407/11/99
Page 9 of 1017. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A:
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta
and contact inhibition to cell cycle arrest. Genes Dev 1994, 8(1):9-22.
18. Drexler HC, Pebler S: Inducible p27(Kip1) expression inhibits proliferation
of K562 cells and protects against apoptosis induction by proteasome
inhibitors. Cell Death Differ 2003, 10(3):290-301.
19. Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL,
Graff JR: The progression of LNCaP human prostate cancer cells to
androgen independence involves decreased FOXO3a expression and
reduced p27KIP1 promoter transactivation. Mol Cancer Res 2005,
3(3):163-169.
20. Tang ED, Nunez G, Barr FG, Guan KL: Negative regulation of the forkhead
transcription factor FKHR by Akt. J Biol Chem 1999, 274(24):16741-16746.
21. Liu BQ, Gao YY, Niu XF, Xie JS, Meng X, Guan Y, Wang HQ: Implication of
unfolded protein response in resveratrol-induced inhibition of K562 cell
proliferation. Biochem Biophys Res Commun 2010, 391(1):778-782.
22. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP:
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in
human glioblastoma multiforme (GBM). Oncogene 2005, 24(3):344-354.
23. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih Ie M, Roden RB:
Ubiquitin-proteasome system stress sensitizes ovarian cancer to
proteasome inhibitor-induced apoptosis. Cancer Res 2006,
66(7):3754-3763.
24. Soligo D, Servida F, Delia D, Fontanella E, Lamorte G, Caneva L, Fumiatti R,
Lambertenghi Deliliers G: The apoptogenic response of human myeloid
leukaemia cell lines and of normal and malignant haematopoietic
progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001,
113(1):126-135.
25. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV:
Tumor growth inhibition induced in a murine model of human Burkitt’s
lymphoma by a proteasome inhibitor. Cancer Res 1998, 58(19):4342-4348.
26. Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y,
Bex F, de The H, Hermine O, et al: Efficacy and mechanism of action of
the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I
associated adult T-cell leukemia/lymphoma. Oncogene 2005,
24(3):419-430.
27. Agrawal D, Hauser P, McPherson F, Dong F, Garcia A, Pledger WJ:
Repression of p27kip1 synthesis by platelet-derived growth factor in
BALB/c 3T3 cells. Mol Cell Biol 1996, 16(8):4327-4336.
28. Srivastava RK, Unterman TG, Shankar S: FOXO transcription factors and
VEGF neutralizing antibody enhance antiangiogenic effects of
resveratrol. Mol Cell Biochem 2010, 337(1-2):201-212.
29. Ganjam GK, Dimova EY, Unterman TG, Kietzmann T: FoxO1 and HNF-4 are
involved in regulation of hepatic glucokinase gene expression by
resveratrol. J Biol Chem 2009, 284(45):30783-30797.
30. Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead
transcription factors mediate cell-cycle regulation by Ras and PKB
through p27kip1. Nature 2000, 404(6779):782-787.
31. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW,
Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, et al: Forkhead
transcription factor FKHR-L1 modulates cytokine-dependent
transcriptional regulation of p27(KIP1). Mol Cell Biol 2000,
20(24):9138-9148.
32. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR:
Forkhead transcription factors are critical effectors of cell death and cell
cycle arrest downstream of PTEN. Mol Cell Biol 2000, 20(23):8969-8982.
33. Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, Liu Y, Feng TT, Meng FY, Liu XL,
Jiang QL, et al: Synergy between proteasome inhibitors and imatinib
mesylate in chronic myeloid leukemia. PLoS One 2009, 4(7):e6257.
34. Shah JJ, Orlowski RZ: Proteasome inhibitors in the treatment of multiple
myeloma. Leukemia 2009, 23(11):1964-1979.
35. Paoluzzi L, Scotto L, Marchi E, Seshan VE, O’Connor OA: The anti-histaminic
cyproheptadine synergizes the antineoplastic activity of bortezomib in
mantle cell lymphoma through its effects as a histone deacetylase
inhibitor. Br J Haematol 2009, 146(6):656-659.
36. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z,
Shen ZX, Chen SJ, et al: The proteasome inhibitor bortezomib interacts
synergistically with the histone deacetylase inhibitor suberoylanilide
hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Leukemia 2009, 23(8):1507-1514.
37. Drexler HC: Synergistic apoptosis induction in leukemic cells by the
phosphatase inhibitor salubrinal and proteasome inhibitors. PLoS One
2009, 4(1):e4161.
38. Touzet O, Philips A: Resveratrol protects against protease inhibitor-
induced reactive oxygen species production, reticulum stress and lipid
raft perturbation. Aids 2010, 24(10):1437-1447.
39. Chakraborty PK, Mustafi SB, Ganguly S, Chatterjee M, Raha S: Resveratrol
induces apoptosis in K562 (chronic myelogenous leukemia) cells by
targeting a key survival protein, heat shock protein 70. Cancer Sci 2008,
99(6):1109-1116.
40. Goswami SK, Das DK: Resveratrol and chemoprevention. Cancer Lett 2009,
284(1):1-6.
41. Jannin B, Menzel M, Berlot JP, Delmas D, Lancon A, Latruffe N: Transport of
resveratrol, a cancer chemopreventive agent, to cellular targets:
plasmatic protein binding and cell uptake. Biochem Pharmacol 2004,
68(6):1113-1118.
42. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, Estrela JM:
Inhibition of cancer growth by resveratrol is related to its low
bioavailability. Free Radic Biol Med 2002, 33(3):387-398.
43. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK: High absorption but
very low bioavailability of oral resveratrol in humans. Drug Metab Dispos
2004, 32(12):1377-1382.
44. Li L, Zhang G, Zhang Y, Tan J, Huang H, Huang B, Lu J: Sodium butyrate-
induced upregulation of p18(INK4C) gene affects K562 cell G (0)/G (1)
arrest and differentiation. Mol Cell Biochem 2008, 319(1-2):9-15.
45. An B, Goldfarb RH, Siman R, Dou QP: Novel dipeptidyl proteasome
inhibitors overcome Bcl-2 protective function and selectively accumulate
the cyclin-dependent kinase inhibitor p27 and induce apoptosis in
transformed, but not normal, human fibroblasts. Cell Death Differ 1998,
5(12):1062-1075.
46. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P: Promoting
apoptosis: a novel activity associated with the cyclin-dependent kinase
inhibitor p27. Cancer Res 1997, 57(24):5441-5445.
47. Wang X, Gorospe M, Huang Y, Holbrook NJ: p27Kip1 overexpression
causes apoptotic death of mammalian cells. Oncogene 1997,
15(24):2991-2997.
48. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, Zhao M,
Miyauchi M, Nikai H: p27Kip1 accumulation by inhibition of proteasome
function induces apoptosis in oral squamous cell carcinoma cells. Clin
Cancer Res 2000, 6(3):916-923.
49. Sun J, Nam S, Lee CS, Li B, Coppola D, Hamilton AD, Dou QP, Sebti SM:
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and
p27KIP1 expression and apoptosis and inhibits the growth of the
human lung adenocarcinoma A-549 in nude mice. Cancer Res 2001,
61(4):1280-1284.
50. Eymin B, Haugg M, Droin N, Sordet O, Dimanche-Boitrel MT, Solary E:
p27Kip1 induces drug resistance by preventing apoptosis upstream of
cytochrome c release and procaspase-3 activation in leukemic cells.
Oncogene 1999, 18(7):1411-1418.
51. Dimanche-Boitrel MT, Micheau O, France D, Hammann A, Duchamp O,
Genne P, Solary E: P27KiP1 overexpression inhibits the growth and
doxorubicin sensitivity of HT29 human colon cancer cells in vivo.
Anticancer Res 2000, 20(2A):849-852.
52. Masuda A, Osada H, Yatabe Y, Kozaki K, Tatematsu Y, Takahashi T, Hida T,
Takahashi T, Takahashi T: Protective function of p27(KIP1) against
apoptosis in small cell lung cancer cells in unfavorable
microenvironments. Am J Pathol 2001, 158(1):87-96.
53. Denicourt C, Dowdy SF: Cip/Kip proteins: more than just CDKs inhibitors.
Genes Dev 2004, 18(8):851-855.
54. Taniguchi T, Endo H, Chikatsu N, Uchimaru K, Asano S, Fujita T, Nakahata T,
Motokura T: Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-
dependent kinase inhibitors during human hematopoiesis. Blood 1999,
93(12):4167-4178.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/99/prepub
doi:10.1186/1471-2407-11-99
Cite this article as: Niu et al.: Resveratrol protects leukemic cells against
cytotoxicity induced by proteasome inhibitors via induction of FOXO1
and p27
Kip1. BMC Cancer 2011 11:99.
Niu et al. BMC Cancer 2011, 11:99
http://www.biomedcentral.com/1471-2407/11/99
Page 10 of 10